Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.69 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.69 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.69 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.69 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 6/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MYLK | Q15746 | 1/20 | 0.39 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072568 | 1.00 | KCNQ3 (0.69) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL5857386 | 0.85 | KCNQ3 (0.54) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL30796116 | 0.85 | KCNQ3 (0.54) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL30322599 | 0.84 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL30364566 | 0.84 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL24051927 | 0.84 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL28942778 | 0.84 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| SCHEMBL28942804 | 0.84 | KCNQ3 (0.56) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| Flindokalner SCHEMBL5144502 | 0.82 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 | |
| Flindokalner SCHEMBL4056222 | 0.82 | KCNQ3 (1.00) | KCNQ3KCNQ2KCNQ4KCNMA1KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
| WO-2016128772-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | KCNMA1, KCNMB1, KCNA1 | KCNQ3 39/4885KCNQ2 31/4885KCNQ4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.